InMode (NASDAQ:INMD) Given New $15.00 Price Target at Jefferies Financial Group

InMode (NASDAQ:INMD - Free Report) had its target price cut by Jefferies Financial Group from $16.00 to $15.00 in a research report sent to investors on Monday morning, Marketbeat.com reports. They currently have a hold rating on the healthcare company's stock.

A number of other analysts have also weighed in on the company. Barclays increased their price objective on InMode from $26.00 to $29.00 and gave the company an "overweight" rating in a research note on Wednesday, February 5th. Needham & Company LLC reaffirmed a "hold" rating on shares of InMode in a research note on Wednesday, April 9th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. Based on data from MarketBeat.com, InMode presently has a consensus rating of "Hold" and a consensus price target of $21.25.

InMode Trading Up 0.1 %

Shares of NASDAQ INMD traded up $0.01 during mid-day trading on Monday, hitting $14.92. The company had a trading volume of 870,722 shares, compared to its average volume of 1,178,040. The stock's 50-day moving average price is $17.68 and its 200-day moving average price is $17.61. The company has a market capitalization of $1.04 billion, a price-to-earnings ratio of 6.35 and a beta of 1.96. InMode has a 1 year low of $13.68 and a 1 year high of $19.85.

Institutional Investors Weigh In On InMode

A number of hedge funds have recently made changes to their positions in the company. Renaissance Technologies LLC increased its holdings in shares of InMode by 2.3% in the 4th quarter. Renaissance Technologies LLC now owns 2,266,618 shares of the healthcare company's stock worth $37,853,000 after buying an additional 50,200 shares during the last quarter. State Street Corp grew its stake in InMode by 3.7% in the 3rd quarter. State Street Corp now owns 2,044,640 shares of the healthcare company's stock worth $34,657,000 after acquiring an additional 73,183 shares in the last quarter. LSV Asset Management increased its position in shares of InMode by 0.4% during the fourth quarter. LSV Asset Management now owns 1,715,071 shares of the healthcare company's stock worth $28,642,000 after acquiring an additional 6,300 shares during the period. Geode Capital Management LLC increased its position in InMode by 0.6% during the 3rd quarter. Geode Capital Management LLC now owns 1,101,951 shares of the healthcare company's stock valued at $18,678,000 after purchasing an additional 6,282 shares during the period. Finally, JPMorgan Chase & Co. boosted its position in InMode by 4.4% during the fourth quarter. JPMorgan Chase & Co. now owns 1,084,241 shares of the healthcare company's stock valued at $18,107,000 after purchasing an additional 45,638 shares in the last quarter. 68.04% of the stock is currently owned by hedge funds and other institutional investors.

InMode Company Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.